Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 3Phase 2 2Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Cytarabine 68Cyclophosphamide 44Methotrexate 41Daunorubicin 38Etoposide 34Vincristine 30Mercaptopurine 28Dexamethasone 24Radiotherapy 22Idarubicin 22Asparaginase 21Thioguanine 20Doxorubicin 19Prednisone 17Peripheral Blood Stem Cell Transplantation 17Imatinib Mesylate 16Busulfan 16pegaspargase 15Mitoxantrone 15Filgrastim 13Leucovorin 11fludarabine phosphate 10Hydrocortisone 10nilotinib 9Tretinoin 8Prednisolone 8Cyclosporine 8Hydroxyurea 7Epoetin Alfa 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia × laromustine × Clear all
NCT00112554 2013-11-06

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
420 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡